{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:08:25Z","timestamp":1780337305991,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/01090"],"award-info":[{"award-number":["PI14\/01090"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01617"],"award-info":[{"award-number":["PI17\/01617"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.biopha.2023.114885","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T23:19:47Z","timestamp":1684279187000},"page":"114885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-191X","authenticated-orcid":false,"given":"Susana","family":"Almenara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Lozano-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cayetano","family":"Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Bellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Palazon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabi\u00e1n","family":"Tar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Franc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Gonzalez-Navajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-858X","authenticated-orcid":false,"given":"Pedro","family":"Zapater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114885_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.biopha.2023.114885_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/liv.13277","article-title":"Prevention and treatment of variceal haemorrhage in 2017","volume":"37","author":"Brunner","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2023.114885_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12072-017-9833-y","article-title":"Pharmacologic prevention of variceal bleeding and rebleeding","volume":"12","author":"Baiges","year":"2018","journal-title":"Hepatol. Int"},{"key":"10.1016\/j.biopha.2023.114885_bib4","first-page":"1","article-title":"Carvedilol attenuates the progression of hepatic fibrosis induced by bile duct ligation","volume":"2017","author":"Tian","year":"2017","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.biopha.2023.114885_bib5","doi-asserted-by":"crossref","first-page":"14327","DOI":"10.1038\/s41598-018-32309-1","article-title":"Anti-fibrotic impact of Carvedilol in a CCl-4 model of liver fibrosis via serum microRNA-200a\/SMAD7 enhancement to bridle TGF-\u03b21\/EMT track","volume":"8","author":"El-Wakeel","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.114885_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1940-6207.CAPR-11-0450","article-title":"Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis","volume":"5","author":"Nkontchou","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.biopha.2023.114885_bib7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MEG.0000000000000677","article-title":"The use of \u03b2-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis","volume":"28","author":"Herrera","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2023.114885_bib8","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/liv.12782","article-title":"Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"35","author":"Thiele","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2023.114885_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/liv.12593","article-title":"The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis","volume":"35","author":"Merli","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2023.114885_bib10","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014Propranolol as an anti-cancer agent","volume":"10","author":"Pantziarka","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.biopha.2023.114885_bib11","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.18632\/oncotarget.14119","article-title":"Use of non-selective \u03b2-blockers is associated with decreased tumor proliferative indices in early stage breast cancer","volume":"8","author":"Montoya","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114885_bib12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10654-017-0304-5","article-title":"Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis","volume":"32","author":"Weberpals","year":"2017","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.biopha.2023.114885_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00432-016-2278-1","article-title":"\u03b2-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives","volume":"143","author":"Coelho","year":"2017","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114885_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00164","article-title":"Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response","volume":"9","author":"Qiao","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2023.114885_bib15","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/liv.13890","article-title":"Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis","volume":"38","author":"Gimenez","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2023.114885_bib16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12072-020-10083-5","article-title":"Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers","volume":"14","author":"Almenara","year":"2020","journal-title":"Hepatol. Int"},{"key":"10.1016\/j.biopha.2023.114885_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/apt.16490","article-title":"Nonselective beta\u2010blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States","volume":"54","author":"Wijarnpreecha","year":"2021","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.114885_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cyto.2018.10.024","article-title":"The imbalance of peripheral interleukin-18 and transforming growth factor-\u03b21 levels in patients with cirrhosis and esophageal varices","volume":"113","author":"Swidnicka-Siergiejko","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2023.114885_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cyto.2016.12.017","article-title":"From stable disease to acute-on-chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis","volume":"91","author":"Fischer","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2023.114885_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5455\/medarh.2021.75.199-203","article-title":"Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis","volume":"75","author":"Rey","year":"2021","journal-title":"Med. Arch."},{"key":"10.1016\/j.biopha.2023.114885_bib21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/gut.25.10.1034","article-title":"Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis","volume":"25","author":"Henriksen","year":"1984","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2023.114885_bib22","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2020-322712","article-title":"Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes","volume":"70","author":"Jachs","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2023.114885_bib23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2023.114885_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155497","article-title":"Alpha and beta adrenoceptors activate interleukin-6 transcription through different pathways in cultured astrocytes from rat spinal cord","volume":"142","author":"Morimoto","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2023.114885_bib25","doi-asserted-by":"crossref","first-page":"G489","DOI":"10.1152\/ajpgi.00012.2022","article-title":"Exaggerated inflammatory response to bacterial products in decompensated cirrhotic patients is orchestrated by interferons IL-6 and IL-8","volume":"322","author":"Kronsten","year":"2022","journal-title":"Am. J. Physiol. -Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2023.114885_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/707254","article-title":"Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response","volume":"2015","author":"El-Emshaty","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.biopha.2023.114885_bib27","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.2147\/IJGM.S326192","article-title":"Adherence to Non-Selective Beta Blockers for Prevention of Variceal Bleeding in Cirrhotic Patients","volume":"Volume 14","author":"An","year":"2021","journal-title":"Int J. Gen. Med"},{"key":"10.1016\/j.biopha.2023.114885_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamacardio.2021.4932","article-title":"Practical recommendations on quantifying and interpreting treatment effects in the presence of terminal competing risks: a review","volume":"7","author":"McCaw","year":"2022","journal-title":"JAMA Cardiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223006753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223006753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:37:14Z","timestamp":1780335434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223006753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":28,"alternative-id":["S0753332223006753"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114885","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114885"}}